365 related articles for article (PubMed ID: 9316529)
1. Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure.
Böhm M; Deutsch HJ; Hartmann D; Rosée KL; Stäblein A
J Am Coll Cardiol; 1997 Oct; 30(4):992-6. PubMed ID: 9316529
[TBL] [Abstract][Full Text] [Related]
2. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure.
Shakar SF; Abraham WT; Gilbert EM; Robertson AD; Lowes BD; Zisman LS; Ferguson DA; Bristow MR
J Am Coll Cardiol; 1998 May; 31(6):1336-40. PubMed ID: 9581729
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of the effectiveness of milrinone to increase force of contraction by stimulation of cardiac beta-adrenoceptors in the failing human heart.
Böhm M; Diet F; Kemkes B; Erdmann E
Klin Wochenschr; 1988 Oct; 66(19):957-62. PubMed ID: 2846949
[TBL] [Abstract][Full Text] [Related]
4. Subsensitivity of the failing human heart to isoprenaline and milrinone is related to beta-adrenoceptor downregulation.
Böhm M; Diet F; Feiler G; Kemkes B; Kreuzer E; Weinhold C; Erdmann E
J Cardiovasc Pharmacol; 1988 Dec; 12(6):726-32. PubMed ID: 2467092
[TBL] [Abstract][Full Text] [Related]
5. Effects of metoprolol on myocardial beta-adrenoceptors and Gi alpha-proteins in patients with congestive heart failure.
Sigmund M; Jakob H; Becker H; Hanrath P; Schumacher C; Eschenhagen T; Schmitz W; Scholz H; Steinfath M
Eur J Clin Pharmacol; 1996; 51(2):127-32. PubMed ID: 8911876
[TBL] [Abstract][Full Text] [Related]
6. PDE3, but not PDE4, reduces β₁ - and β₂-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients.
Molenaar P; Christ T; Hussain RI; Engel A; Berk E; Gillette KT; Chen L; Galindo-Tovar A; Krobert KA; Ravens U; Levy FO; Kaumann AJ
Br J Pharmacol; 2013 Jun; 169(3):528-38. PubMed ID: 23489141
[TBL] [Abstract][Full Text] [Related]
7. The inotropic and hemodynamic effects of intravenous milrinone when reflex adrenergic stimulation is suppressed by beta-adrenergic blockade.
Travill CM; Pugh S; Noble MI
Clin Ther; 1994; 16(5):783-92. PubMed ID: 7859237
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure.
Mager G; Klocke RK; Kux A; Höpp HW; Hilger HH
Am Heart J; 1991 Jun; 121(6 Pt 2):1974-83. PubMed ID: 1852090
[TBL] [Abstract][Full Text] [Related]
9. Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone.
Earl GL; Verbos-Kazanas MA; Fitzpatrick JM; Narula J
Pharmacotherapy; 2007 May; 27(5):697-706. PubMed ID: 17461705
[TBL] [Abstract][Full Text] [Related]
10. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience.
Shaddy RE; Tani LY; Gidding SS; Pahl E; Orsmond GS; Gilbert EM; Lemes V
J Heart Lung Transplant; 1999 Mar; 18(3):269-74. PubMed ID: 10328154
[TBL] [Abstract][Full Text] [Related]
11. Decreased inotropic but relatively preserved relaxation response to cyclic adenosine monophosphate-dependent agents in myopathic human myocardium.
Gutstein DE; Flemmal K; Bruce E; Travers KE; Gwathmey JK; Ransil BJ; Markis JE; Grossman W; Morgan JP
J Card Fail; 1996 Dec; 2(4):285-92. PubMed ID: 8989643
[TBL] [Abstract][Full Text] [Related]
12. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Packer M; Carver JR; Rodeheffer RJ; Ivanhoe RJ; DiBianco R; Zeldis SM; Hendrix GH; Bommer WJ; Elkayam U; Kukin ML
N Engl J Med; 1991 Nov; 325(21):1468-75. PubMed ID: 1944425
[TBL] [Abstract][Full Text] [Related]
13. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol.
Lowes BD; Tsvetkova T; Eichhorn EJ; Gilbert EM; Bristow MR
Int J Cardiol; 2001 Dec; 81(2-3):141-9. PubMed ID: 11744130
[TBL] [Abstract][Full Text] [Related]
14. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart.
Gilbert EM; Abraham WT; Olsen S; Hattler B; White M; Mealy P; Larrabee P; Bristow MR
Circulation; 1996 Dec; 94(11):2817-25. PubMed ID: 8941107
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of positive inotropic phosphodiesterase III inhibitors.
Honerjäger P
Eur Heart J; 1989 Aug; 10 Suppl C():25-31. PubMed ID: 2553411
[TBL] [Abstract][Full Text] [Related]
16. Metoprolol in dilated cardiomyopathy: is it possible to identify factors predictive of improvement? The Heart Muscle Disease Study Group.
DiLenarda A; Gregori D; Sinagra G; Lardieri G; Perkan A; Pinamonti B; Salvatore L; Secoli G; Zecchin M; Camerini F
J Card Fail; 1996 Jun; 2(2):87-102. PubMed ID: 8798110
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic achievements of phosphodiesterase inhibitors and the future.
Jewitt DE
Eur Heart J; 1989 Aug; 10 Suppl C():53-9. PubMed ID: 2680498
[TBL] [Abstract][Full Text] [Related]
18. Effect of metoprolol on rest and exercise left ventricular systolic and diastolic function in idiopathic dilated cardiomyopathy.
Clements IP; Miller WL
Am Heart J; 2001 Feb; 141(2):259. PubMed ID: 11174349
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol.
Metra M; Giubbini R; Nodari S; Boldi E; Modena MG; Dei Cas L
Circulation; 2000 Aug; 102(5):546-51. PubMed ID: 10920067
[TBL] [Abstract][Full Text] [Related]
20. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone.
Monrad ES; McKay RG; Baim DS; Colucci WS; Fifer MA; Heller GV; Royal HD; Grossman W
Circulation; 1984 Dec; 70(6):1030-7. PubMed ID: 6499142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
